|
|
| | 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Basic information |
| | 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Chemical Properties |
| Boiling point | 803.7±65.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | pka | 12.13±0.43(Predicted) |
| | 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Usage And Synthesis |
| Uses | Sacibertinib is a tyrosine kinase (Trk) inhibitor with EC50 value of 110 nM and 244 nM for EGFR-TK phosphorylation and HER2, respectively. Antineoplastic activity[1]. | | IC 50 | EGFR-TK phosphorylation: 110 nM (EC50); HER2: 244 nM (EC50) | | References | [1] Hesheng Zhang, et al. Cyanoquinoline derivatives. CA2802130A1 (Example 138) [2] International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022. |
| | 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Preparation Products And Raw materials |
|